Bayer and J&J file Xarelto for stroke prevention
This article was originally published in Scrip
Executive Summary
Bayer and partner Johnson & Johnson have filed for European and US approval of Bayer's rivaroxaban (Xarelto) for use in stroke prevention. This follows promising data from the ROCKET AF trial published last November (scripintelligence.com, 2 November 2010).